|
May 28
|
Top Analyst Reports for Alphabet, Bank of America & Roche
|
|
May 28
|
Mapping out opportunities to reduce emissions in clinical trials
|
|
May 27
|
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
|
|
May 26
|
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
|
|
May 26
|
Roche and Broad Clinical Labs to partner on advancing SBX technology
|
|
May 25
|
Tandem Diabetes and Roche Reach a Patent Settlement
|
|
May 24
|
Tandem Diabetes, Roche enter patent settlement agreement
|
|
May 23
|
Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication
|
|
May 23
|
Genentech to onshore US manufacturing amid rising drug pricing tensions
|
|
May 23
|
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
|
|
May 23
|
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
|
|
May 23
|
Bayer’s Eylea set for longer treatment intervals to challenge Roche’s Vabysmo
|
|
May 23
|
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology
|
|
May 23
|
New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients
|
|
May 23
|
New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients
|
|
May 22
|
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy
|
|
May 22
|
FDA approves Roche’s Susvimo for diabetic retinopathy
|
|
May 1
|
'Declare victory and move on': Eli Lilly CEO on Trump tariff threat
|
|
May 1
|
Roche Holding AG (RHHBY) is a Great Momentum Stock: Should You Buy?
|
|
Apr 30
|
How Roche revitalized customer analytics across its data estate
|